LIFECOME BIOCHEMISTRY CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.76 CNY | -4.11% |
|
+3.30% | -35.28% |
| Jun. 24 | Lifecome Biochemistry Co.,Ltd.(XSEC:002868) dropped from S&P Global BMI Index | CI |
| May. 22 | Lifecome Biochemistry Names Chairman | MT |
| Sales 2022 | 330M 45.37M | Sales 2023 | 507M 69.73M | Capitalization | 3.26B 449M |
|---|---|---|---|---|---|
| Net income 2022 | -122M -16.78M | Net income 2023 | -222M -30.53M | EV / Sales 2022 | 25.8 x |
| Net Debt 2022 | 372M 51.14M | Net Debt 2023 | 1B 138M | EV / Sales 2023 | 8.41 x |
| P/E ratio 2022 |
-67.2
x | P/E ratio 2023 |
-14.8
x | Employees | 992 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 28.22% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.11% | ||
| 1 week | +4.48% | ||
| Current month | +3.46% | ||
| 1 month | -16.96% | ||
| 3 months | -25.14% | ||
| 6 months | -35.28% | ||
| Current year | -35.28% |
1 week
13.10
14.63
1 month
13.0116.59
Current year
13.0133.00
1 year
13.0137.43
3 years
9.0065.90
5 years
9.0065.90
10 years
9.0065.90
| Managers | Title | Age | Since |
|---|---|---|---|
Tan Ping Lai
CEO | Chief Executive Officer | 60 | 09-11-30 |
Zhong Shou Bao
DFI | Director of Finance/CFO | 54 | 12-05-27 |
Qiu Xian Zheng
CTO | Chief Tech/Sci/R&D Officer | 70 | 12-05-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tan Ping Lai
CEO | Chief Executive Officer | 60 | 09-11-30 |
Wei Min Zhang
PRN | Corporate Officer/Principal | 65 | 03-05-31 |
Zhen Wu Feng
CHM | Chairman | 59 | 06-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-02 | 13.76 | -4.11% | 2,626,560 |
| 24-07-01 | 14.35 | +7.89% | 3,190,981 |
| 24-06-28 | 13.3 | +0.76% | 843,050 |
| 24-06-27 | 13.2 | -2.00% | 846,050 |
| 24-06-26 | 13.47 | +1.13% | 647,436 |
End-of-day quote Shenzhen S.E., July 01, 2024
More quotes
LIFECOME BIOCHEMISTRY CO LTD is a China-based company principally engaged in the development, production and sales of veterinary drugs. The Company's businesses include the production and sales of veterinary premixes, veterinary raw materials, veterinary soluble powders, food additives, feed additives and biological pesticide. Its products include bacitracin products, colistin sulfate products, flavomycin products, natamycin, Bacillus subtilis, Bacillus licheniformis, mixed probiotics, Bacillus thuringiensis series and Jinggangmycin series. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-09-01
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -35.28% | 307M | |
| -11.43% | 78.75B | |
| -5.97% | 6.97B | |
| +22.12% | 3.7B | |
| -6.12% | 3.03B | |
| +12.67% | 1.66B | |
| -33.80% | 1.12B | |
| -36.68% | 1.07B | |
| -31.31% | 931M | |
| -16.35% | 891M |
- Stock Market
- Equities
- 002868 Stock
